NO304940B1 - Salmeterol-xinafoat med regulert partikkelstorrelse - Google Patents
Salmeterol-xinafoat med regulert partikkelstorrelseInfo
- Publication number
- NO304940B1 NO304940B1 NO19955355A NO955355A NO304940B1 NO 304940 B1 NO304940 B1 NO 304940B1 NO 19955355 A NO19955355 A NO 19955355A NO 955355 A NO955355 A NO 955355A NO 304940 B1 NO304940 B1 NO 304940B1
- Authority
- NO
- Norway
- Prior art keywords
- pct
- particle size
- salmeterol xinafoate
- controlled particle
- sec
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
- B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Semiconductor Integrated Circuits (AREA)
- Investigating Or Analyzing Materials By The Use Of Fluid Adsorption Or Reactions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB939313650A GB9313650D0 (en) | 1993-07-01 | 1993-07-01 | Method and apparatus for the formation of particles |
PCT/GB1994/001425 WO1995001324A1 (en) | 1993-07-01 | 1994-06-30 | Salmeterol xinafoate with controlled particle size |
Publications (3)
Publication Number | Publication Date |
---|---|
NO955355D0 NO955355D0 (no) | 1995-12-29 |
NO955355L NO955355L (no) | 1996-02-29 |
NO304940B1 true NO304940B1 (no) | 1999-03-08 |
Family
ID=10738146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19955355A NO304940B1 (no) | 1993-07-01 | 1995-12-29 | Salmeterol-xinafoat med regulert partikkelstorrelse |
Country Status (20)
Country | Link |
---|---|
US (1) | US5795594A (no) |
EP (1) | EP0706507B1 (no) |
JP (1) | JP3839042B2 (no) |
CN (1) | CN1062854C (no) |
AT (1) | ATE184870T1 (no) |
AU (1) | AU684795B2 (no) |
BR (1) | BR9406995A (no) |
CA (1) | CA2165830C (no) |
DE (1) | DE69420844T2 (no) |
DK (1) | DK0706507T3 (no) |
ES (1) | ES2138085T3 (no) |
FI (1) | FI956343A (no) |
GB (1) | GB9313650D0 (no) |
GR (1) | GR3032065T3 (no) |
HK (1) | HK1004216A1 (no) |
HU (1) | HUT73733A (no) |
NO (1) | NO304940B1 (no) |
NZ (1) | NZ267696A (no) |
RU (1) | RU2136655C1 (no) |
WO (1) | WO1995001324A1 (no) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2234957C (en) * | 1995-10-17 | 2006-12-19 | Inge B. Henriksen | Insoluble drug delivery |
US5874029A (en) * | 1996-10-09 | 1999-02-23 | The University Of Kansas | Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent |
US5833891A (en) * | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6652837B1 (en) | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
US20020052310A1 (en) * | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
GB9703673D0 (en) * | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
GB9806462D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Improved compositions for inhalation |
GB9808802D0 (en) * | 1998-04-24 | 1998-06-24 | Glaxo Group Ltd | Pharmaceutical formulations |
GB9810559D0 (en) * | 1998-05-15 | 1998-07-15 | Bradford Particle Design Ltd | Method and apparatus for particle formation |
US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
SE9804001D0 (sv) * | 1998-11-23 | 1998-11-23 | Astra Ab | New process |
US6630121B1 (en) | 1999-06-09 | 2003-10-07 | The Regents Of The University Of Colorado | Supercritical fluid-assisted nebulization and bubble drying |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
GB9915975D0 (en) * | 1999-07-07 | 1999-09-08 | Bradford Particle Design Ltd | Method for the formation of particles |
US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
US6749835B1 (en) | 1999-08-25 | 2004-06-15 | Advanced Inhalation Research, Inc. | Formulation for spray-drying large porous particles |
CA2382821A1 (en) * | 1999-08-25 | 2001-03-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
US20010036481A1 (en) * | 1999-08-25 | 2001-11-01 | Advanced Inhalation Research, Inc. | Modulation of release from dry powder formulations |
CA2317999C (en) * | 1999-09-11 | 2004-11-09 | Glaxo Group Limited | Pharmaceutical formulation of fluticasone propionate |
FR2803538B1 (fr) * | 1999-12-15 | 2002-06-07 | Separex Sa | Procede et dispositif de captage de fines particules par percolation dans un lit de granules |
US6669960B2 (en) | 1999-12-21 | 2003-12-30 | Rxkinetix, Inc. | Particulate drug-containing products and method of manufacture |
US6761909B1 (en) | 1999-12-21 | 2004-07-13 | Rxkinetix, Inc. | Particulate insulin-containing products and method of manufacture |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
GB0015981D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
US8551526B2 (en) * | 2000-11-03 | 2013-10-08 | Board Of Regents, The University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
US6756062B2 (en) | 2000-11-03 | 2004-06-29 | Board Of Regents University Of Texas System | Preparation of drug particles using evaporation precipitation into aqueous solutions |
GB0027357D0 (en) | 2000-11-09 | 2000-12-27 | Bradford Particle Design Plc | Particle formation methods and their products |
CA2433335C (en) | 2000-12-29 | 2010-04-20 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
EP1363726B1 (en) * | 2001-02-26 | 2004-09-01 | Dompé S.P.A. | Apparatus and method for micron and submicron particle formation |
WO2003006223A1 (en) * | 2001-07-10 | 2003-01-23 | University Technology Corporation | Devices and methods for the production of particles |
GB0117403D0 (en) * | 2001-07-17 | 2001-09-05 | Pharmacia & Upjohn Spa | Solvent-free crystalline anthracycline derivatives |
GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
GB0117696D0 (en) * | 2001-07-20 | 2001-09-12 | Bradford Particle Design Plc | Particle information |
BR0213155A (pt) * | 2001-10-10 | 2004-09-14 | Boehringer Ingelheim Pharma | Processamento de pó com fluidos gasosos pressurizados |
WO2003043603A1 (en) * | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Particulate compositions for improving solubility of poorly soluble agents |
US7182961B2 (en) * | 2001-11-20 | 2007-02-27 | Advanced Inhalation Research, Inc. | Particulate compositions for pulmonary delivery |
CA2468958C (en) | 2001-12-19 | 2012-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
EP1485068A2 (en) * | 2002-03-20 | 2004-12-15 | Advanced Inhalation Research, Inc. | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION |
US7008644B2 (en) * | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
US20050163725A1 (en) * | 2002-03-20 | 2005-07-28 | Blizzard Charles D. | Method for administration of growth hormone via pulmonary delivery |
GB0216562D0 (en) | 2002-04-25 | 2002-08-28 | Bradford Particle Design Ltd | Particulate materials |
AU2003226567A1 (en) * | 2002-04-25 | 2003-11-10 | Nektar Therapeutics Uk Ltd | Particulate materials |
US9339459B2 (en) | 2003-04-24 | 2016-05-17 | Nektar Therapeutics | Particulate materials |
US20040197412A1 (en) * | 2002-12-19 | 2004-10-07 | Baxter International, Inc. | Process for preparing pharmaceutical formulations using supercritical fluids |
US20040152720A1 (en) * | 2002-12-20 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powdered medicaments containing a tiotropium salt and salmeterol xinafoate |
DE10351663A1 (de) * | 2002-12-20 | 2004-07-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat |
AU2003302329B2 (en) | 2002-12-30 | 2010-01-07 | Novartis Ag | Prefilming atomizer |
US6915966B2 (en) * | 2003-01-29 | 2005-07-12 | Specialty Minerals (Michigan) Inc. | Apparatus for the gunning of a refractory material and nozzles for same |
MY147403A (en) * | 2003-04-29 | 2012-11-30 | Kowa Co | Composition containing medicine extremely slightly solube in water and method for preparation thereof |
EP1624862B1 (en) | 2003-05-08 | 2014-12-31 | Nektar Therapeutics | Particulate materials |
JP4206317B2 (ja) * | 2003-09-10 | 2009-01-07 | 花王株式会社 | 有機板状粒子の製造方法 |
GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
EP1949891A1 (en) | 2004-10-12 | 2008-07-30 | Generics (UK) Limited | Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister |
ES2317306T3 (es) * | 2004-10-12 | 2009-04-16 | Generics (Uk) Limited | Procedimiento para la preparacion de formulaciones en aerosol en suspension, en el que las particulas se forman por precipitacion dentro de un frasco de aerosol. |
US7854397B2 (en) * | 2005-01-21 | 2010-12-21 | Specialty Minerals (Michigan) Inc. | Long throw shotcrete nozzle |
WO2007009164A1 (en) | 2005-07-15 | 2007-01-25 | Eiffel Technologies Limited | Method of particle formation |
US20070021605A1 (en) * | 2005-07-20 | 2007-01-25 | Rolf Keltjens | Process and composition for making olanzapine form i |
WO2007020080A1 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | A process for making olanzapine form i |
EP1957964A2 (en) * | 2005-12-07 | 2008-08-20 | Wyeth Pharmaceuticals | Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry |
WO2007134845A2 (en) * | 2006-05-18 | 2007-11-29 | Synthon B.V. | Olanzapine pharmaceutical composition |
US20080138409A1 (en) * | 2006-09-29 | 2008-06-12 | Osinga Niels J | Olanzapine pharmaceutical composition |
CN1973812B (zh) * | 2006-11-03 | 2010-12-08 | 谭登平 | 一种将超临界二氧化碳萃取物固体粉末化的方法 |
CA2677838C (en) | 2007-02-11 | 2017-08-01 | Map Pharmaceuticals, Inc. | Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile |
EP2127641A1 (en) | 2008-05-26 | 2009-12-02 | Inke, S.A. | Micronisable form of salmeterol xinafoate |
WO2012032546A2 (en) | 2010-09-08 | 2012-03-15 | Cadila Healthcare Limited | Process for the preparation of salmeterol and its intermediates |
MX350838B (es) | 2011-02-11 | 2017-09-18 | Grain Proc Corporation * | Composicion de sal. |
US9132363B2 (en) | 2012-11-20 | 2015-09-15 | Apeks Llc | Extraction system |
US9908062B2 (en) | 2012-11-20 | 2018-03-06 | Andrew Paul Joseph | Extraction apparatus and method |
JP2021141003A (ja) * | 2020-03-07 | 2021-09-16 | エムテックスマート株式会社 | 2次電池の製造方法または2次電池 |
WO2021219230A1 (en) | 2020-04-30 | 2021-11-04 | Paolo Fiorina | Antiviral treatment |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3744329A1 (de) * | 1987-12-28 | 1989-07-06 | Schwarz Pharma Gmbh | Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung |
JP3280974B2 (ja) * | 1991-12-12 | 2002-05-13 | グラクソ、グループ、リミテッド | 医 薬 |
US5509404A (en) * | 1994-07-11 | 1996-04-23 | Aradigm Corporation | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values |
-
1993
- 1993-07-01 GB GB939313650A patent/GB9313650D0/en active Pending
-
1994
- 1994-06-30 HU HU9503772A patent/HUT73733A/hu unknown
- 1994-06-30 JP JP50336895A patent/JP3839042B2/ja not_active Expired - Lifetime
- 1994-06-30 ES ES94918982T patent/ES2138085T3/es not_active Expired - Lifetime
- 1994-06-30 WO PCT/GB1994/001425 patent/WO1995001324A1/en active IP Right Grant
- 1994-06-30 AU AU70070/94A patent/AU684795B2/en not_active Ceased
- 1994-06-30 CN CN94193201A patent/CN1062854C/zh not_active Expired - Lifetime
- 1994-06-30 CA CA002165830A patent/CA2165830C/en not_active Expired - Lifetime
- 1994-06-30 NZ NZ267696A patent/NZ267696A/en not_active IP Right Cessation
- 1994-06-30 DE DE69420844T patent/DE69420844T2/de not_active Expired - Lifetime
- 1994-06-30 BR BR9406995A patent/BR9406995A/pt not_active Application Discontinuation
- 1994-06-30 US US08/564,278 patent/US5795594A/en not_active Expired - Lifetime
- 1994-06-30 EP EP94918982A patent/EP0706507B1/en not_active Expired - Lifetime
- 1994-06-30 DK DK94918982T patent/DK0706507T3/da active
- 1994-06-30 RU RU96102011A patent/RU2136655C1/ru active
- 1994-06-30 AT AT94918982T patent/ATE184870T1/de not_active IP Right Cessation
-
1995
- 1995-12-29 NO NO19955355A patent/NO304940B1/no not_active IP Right Cessation
- 1995-12-29 FI FI956343A patent/FI956343A/fi unknown
-
1998
- 1998-04-23 HK HK98103417A patent/HK1004216A1/xx not_active IP Right Cessation
-
1999
- 1999-12-07 GR GR990403154T patent/GR3032065T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU684795B2 (en) | 1998-01-08 |
HK1004216A1 (en) | 1998-11-20 |
CA2165830A1 (en) | 1995-01-12 |
ATE184870T1 (de) | 1999-10-15 |
FI956343A0 (fi) | 1995-12-29 |
DE69420844D1 (de) | 1999-10-28 |
JP3839042B2 (ja) | 2006-11-01 |
US5795594A (en) | 1998-08-18 |
DK0706507T3 (da) | 2000-04-10 |
NZ267696A (en) | 1997-11-24 |
AU7007094A (en) | 1995-01-24 |
CN1062854C (zh) | 2001-03-07 |
GR3032065T3 (en) | 2000-03-31 |
EP0706507B1 (en) | 1999-09-22 |
HUT73733A (en) | 1996-09-30 |
RU2136655C1 (ru) | 1999-09-10 |
FI956343A (fi) | 1996-02-15 |
ES2138085T3 (es) | 2000-01-01 |
EP0706507A1 (en) | 1996-04-17 |
CN1129932A (zh) | 1996-08-28 |
NO955355D0 (no) | 1995-12-29 |
GB9313650D0 (en) | 1993-08-18 |
HU9503772D0 (en) | 1996-02-28 |
NO955355L (no) | 1996-02-29 |
WO1995001324A1 (en) | 1995-01-12 |
CA2165830C (en) | 2005-04-26 |
BR9406995A (pt) | 1996-09-10 |
DE69420844T2 (de) | 2000-03-16 |
JPH08512047A (ja) | 1996-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0706507T3 (da) | Salmeterolxinafoat med kontrolleret partikelstørrelse | |
ATE366568T1 (de) | Aerosolformulierungen von salmeterol xinafoate | |
ES2157993T3 (es) | Benzoilguanidinas, su preparacion y su uso en medicamentos. | |
DE69213010D1 (de) | Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden. | |
NO308029B1 (no) | Inhibitorer av <beta>-amyloidproteinproduksjon og farmasøytisk preparat inneholdende disse | |
IL105541A0 (en) | Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same | |
FI953442A0 (fi) | Gonadotropiinia sisältäviä pakastekuivattuja pallosia | |
IT8903526A0 (it) | Metodo e dispositivo per l'avanzamento, in successione, di prodotti appiattiti | |
HUP9700574A3 (en) | N,n-dimethyl-(3-aryl-but-3-ene)-amine derivatives, pharmaceutical compositions containing them and process for the preparation thereof | |
ITMO920035A0 (it) | Flacone contagocce particolarmente per prodotti farmaceutici attivabili all'uso per miscelare | |
ZA976967B (en) | Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the of said device. | |
ATE325803T1 (de) | Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung | |
IL88971A0 (en) | Disubstituted pyridines,their preparation and pharmaceutical compositions containing them | |
DE69327812D1 (de) | Arsen-enthaltende arzneimittel zur behandlung des chronischen ermüdungssyndroms | |
AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. | |
DK0654028T3 (da) | 3- og 5-substituerede 1,2,3,4-oxatriazol-5-iminforbindelser og fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende disse forbindelser samt forbindelsernes anvendelse til fremstilling af lægemidler | |
IT1239273B (it) | Procedimento di preparazione di aromi naturali al tartufo e prodotti ottenuti. | |
IT1228902B (it) | Procedimento ed impianto per la preparazione di prodotti farmaceutici in genere. | |
DK8291D0 (da) | Praeparat omfattende en aktiv bestanddel, fortrinsvis i pulver- eller partikelform, samt en baerer for den aktive bestanddel og fremgangsmaade til fremstilling af et saadant praeparat | |
RU2000118524A (ru) | Способ лечения больных красным плоским лишаем | |
TH14468A (th) | " วิธีการดำเนินกรรมวิธีกับมวลชีวภาพประเภทลิกโนเซลลูโลส " | |
DE60210268D1 (de) | Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten | |
IT1228310B (it) | Impianto di sterilizzazione per sostanze alimentari in particelle. | |
GEP19991586B (en) | Pharmaceutical Formulation | |
IT8806983V0 (it) | Gruppo disgregatore, trinciatore, miscelatore e impastatore di alimenti per allevamenti zootecnici o per il trattamento di materiali in campo industriale. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: GLAXO GROUP LTD, GB |
|
MK1K | Patent expired |